Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
复制标题
免疫检查点抑制剂联合化疗/贝伐单抗治疗EGFR突变重度晚期肺癌患者的回顾性分析
DOI：
10.21037/jtd-20-3520
复制
发表时间：
2021-05
影响因子：
2.5
通讯作者：
Feng J
中科院分区：
文献类型：
--
作者：
Hu R;Zhao Z;Shi Y;Shi M;Xia G;Yu S;Feng J
背景 EGFR 突变肺癌对抗程序性死亡 1 (PD-1)/程序性死亡配体 1 (PD-L1) 单一疗法反应不佳。 EGFR突变肺癌患者能否从抗PD-1/PD-L1联合其他药物治疗中获益仍存在争议。我们回顾性评估了 PD-1 抑制剂联合其他药物（化疗和/或贝伐珠单抗）在 EGFR 突变肺癌患者中的安全性和有效性，这些患者在接受 EGFR-TKI 治疗后出现进展，以确定抗 PD-1/PD-L1 疗法联合化疗或/和贝伐珠单抗治疗在重度治疗的 EGFR 突变肺癌患者中的活性。 癌症。方法 我们确定了 56 例 EGFR 突变肺癌患者，单独接受 PD-1/PD-L1 抑制剂治疗或联合化疗/贝伐单抗治疗。使用 RECIST v1.1 评估客观缓解率。不良事件 (AE) 根据美国国家癌症研究所不良事件通用术语标准 v4.0 进行分级。该研究是根据《赫尔辛基宣言》（2013 年修订）进行的。该研究经江苏省肿瘤医院学术伦理委员会批准。 （NO. 2019 160），并且放弃了本次回顾性分析的个人同意。结果 56例患者中有6例（10.7%）获得客观缓解，疾病控制率为53.6%（30/56）。中位无进展生存期 (PFS) 为 3.33 个月，95% CI 为 1.58-5.08 个月。没有患者获得完全缓解。所有 6 名获得 PR 的患者均接受 PD-1 抑制剂联合化疗或贝伐珠单抗治疗。获得 PR 的 6 名患者中有 3 名接受了放疗联合 PD-1 抑制剂治疗。以PD-1抑制剂为基础的治疗作为二线治疗的患者比以PD-1抑制剂为基础的治疗作为三线或晚线治疗的患者表现出相对更长的PFS和更高的客观缓解率（PFS：5.50 vs. 3.27个月，P=0.301；客观缓解率：25.0% vs. 6.82%，P=0.071）。没有观察到额外的 AE 特征。结论 PD-1抑制剂联合化疗/贝伐珠单抗治疗对靶向治疗无效后接受重治疗的晚期EGFR突变肺癌显示出可接受的毒性特征和中等疗效。
Background EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs remains controversial. We retrospectively evaluated the safety and efficacy of the PD-1 inhibitor combined with other drugs (chemotherapy and/or bevacizumab) in patients with EGFR-mutated lung cancer, who have progressed on EGFR–TKI treatment to determine the activity of the anti-PD-1/PD-L1 therapy combined with chemotherapy or/and bevacizumab therapy in heavily treated patients with EGFR-mutated lung cancer. Methods We identified 56 patients with EGFR-mutated lung cancer treated with PD-1/PD-L1 inhibitors alone or combined with the chemotherapy/bevacizumab therapy. The objective response rates were assessed using RECIST v1.1. Adverse events (AEs) were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Academic Ethics Committee of Jiangsu Cancer Hospital. (NO. 2019 160), and individual consent for this retrospective analysis was waived. Results Objective responses were observed in 6 of 56 (10.7%) patients, and the disease control rate was 53.6% (30/56). The median progression-free survival (PFS) was 3.33 months with 95% CI of 1.58–5.08 months. No patient achieved a complete response. All six patients that achieved PR were treated with the PD-1 inhibitor combined with chemotherapy or bevacizumab therapy. Three of the six patients who achieved PR were treated with radiotherapy combined with PD-1 inhibitor-based therapy. Patients treated with the PD-1 inhibitor-based therapy as second-line therapy showed relatively longer PFS and higher objective response rates than those treated with PD-1 inhibitor-based therapy as third- or late-line therapy (PFS: 5.50 vs. 3.27 months, P=0.301; objective response rates: 25.0% vs. 6.82%, P=0.071). No additional AE profile was observed. Conclusions The PD-1 inhibitor combined with the chemotherapy/bevacizumab therapy showed acceptable toxicity profile and moderate efficacy on heavily treated advanced EGFR-mutated lung cancer after the exhaustion of target therapy.
登录
查看更多内容
DOI：
10.1016/j.jtho.2018.03.035
发表时间：
2018-08
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者：
Garon EB
DOI：
10.1158/1078-0432.ccr-15-3101
发表时间：
2016-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Gainor JF;Shaw AT;Sequist LV;Fu X;Azzoli CG;Piotrowska Z;Huynh TG;Zhao L;Fulton L;Schultz KR;Howe E;Farago AF;Sullivan RJ;Stone JR;Digumarthy S;Moran T;Hata AN;Yagi Y;Yeap BY;Engelman JA;Mino-Kenudson M
通讯作者：
Mino-Kenudson M
影响因子：
51.1
作者：
Zhou, Caicun;Wu, Yi-Long;You, Changxuan
通讯作者：
You, Changxuan
影响因子：
5.3
作者：
Liu, Si-yang;Dong, Zhong-yi;Wu, Yi-Long
通讯作者：
Wu, Yi-Long
影响因子：
158.5
作者：
Soria, J. -C.;Ohe, Y.;Nguyen, Nhung
通讯作者：
Nguyen, Nhung